CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Long-Term Debt, Maturity, after Year Five
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) had Long-Term Debt, Maturity, after Year Five of $1.17 million as of 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2026-02-18
- 2025-12-27: Long-Term Debt, Maturity, after Year Five $1.17M.
- 2024-12-28: Long-Term Debt, Maturity, after Year Five $504.57M.
- 2023-12-30: Long-Term Debt, Maturity, after Year Five $1.00B.
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $1.50B.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2025-12-27 | $1.17M 10-K · filed 2026-02-18 |
| 2024-12-28 | $504.57M 10-K · filed 2025-02-19 |
| 2023-12-30 | $1.00B 10-K · filed 2024-02-14 |
| 2022-12-31 | $1.50B 10-K · filed 2023-02-22 |
| 2021-12-25 | $1.50B 10-K · filed 2022-02-16 |
| 2020-12-26 | $1.00B 10-K · filed 2021-02-17 |
| 2019-12-28 | $1.00B 10-K · filed 2020-02-11 |
| 2018-12-29 | $500.00M 10-K · filed 2019-02-13 |
| 2012-12-29 | $0.00 10-K · filed 2013-02-27 |
| 2011-12-31 | $0.00 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |